PureTech Announces New Therapeutic Candidate LYT-310, An Oral CBD Prodrug
PureTech Health plc (NASDAQ: PRTC) (LSE:PRTC) announced the nomination of a new therapeutic candidate, LYT-310, which is an oral CBD prodrug and the second therapeutic candidate developed from PureTech’s Glyph platform to be advanced
